Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study

导出原文传递

翻译打印收藏纠错

作者： Br?ckelmann Paul J. ^[1] ; Zagadailov Erin A. ^[2] ; Corman Shelby L. ^[3] ; Chirikov Viktor ^[4] ; Johnson Courtney ^[5] ; Macahilig Cynthia ^[6] ; Seal Brian ; Dalal Mehul R. ; Illidge Tim

作者单位： AstraZenecaGaithersburg,MD,USA ^[1] Institute of Cancer SciencesUniversity of ManchesterManchester,UK ^[2] Pharmerit InternationalBethesda,MD,USA ^[3] Medical Data AnalyticsParsippany,NJ,USA ^[4] Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company ^[5] Department I of Internal Medicine and German Hodgkin Study Group (GHSG)University Hospital of ^[6]

关键词 ASCT‐ineligible brentuximab vedotin Hodgkin lymphoma relapsed

发布时间 2019-09-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交